Sea’s pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system) ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on ...

The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 ...

The CNS market’s decade-long stagnation was driven by the high cost, complexity, and risk of drug development.

An American neurologist and an Italian epidemiologist whose work revolutionised the treatment of multiple sclerosis yesterday ...

Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show g ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver ...

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link ...

pharmacovigilance and patient advocacy for central nervous system (CNS) and lysosomal storage genetic medicines. She also was an integral part of the company’s ALS and rare disease strategy team.

Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, comp ...